

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	EMvision Medical Devices Ltd
ABN	38 620 388 230

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Philip Dubois
Date of last notice	2 October 2020

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	BONATA PTY LTD <AZTEC INVESTMENT A/C> - Controller of trustee and beneficiary of trust ALPHA SUPER PTY LTD <DUBOIS SUPERANNATION A/C> - Controller of trustee and beneficiary of super fund
Date of change	7 December 2020
No. of securities held prior to change	BONATA PTY LTD <AZTEC INVESTMENT A/C> 7,500 ordinary shares (EMV) ALPHA SUPER PTY LTD <DUBOIS SUPERANNATION A/C> 40,000 ordinary shares (EMV)
Class	Unlisted options

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Number acquired	500,000
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil cash consideration. Refer to 2020 Annual General Meeting Notice of Meeting for estimated valuation details and assumptions.
No. of securities held after change	BONATA PTY LTD <AZTEC INVESTMENT A/C> 7,500 ordinary shares (EMV) ALPHA SUPER PTY LTD <DUBOIS SUPERANNATION A/C> 40,000 ordinary shares (EMV) 500,000 unlisted Series E options, exercise price \$3.95, expiry date 29 September 2023
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of unlisted options following approval at Annual General Meeting.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.